Efficacy of aficamten in obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis.

ABSTRACT:

Background

Obstructive hypertrophic cardiomyopathy (oHCM), a morbid hereditary condition, is characterized by asymmetrical intraventricular septum enlargement, obstructing blood flow from the left ventricle outflow tract (LVOT) and lowering cardiac output. Aficamten, a novel selective, oral myosin inhibitor, has been suggested to reduce myocardial hypercontractility and decrease LVOT gradient in oHCM.

Methods

A comprehensive search was conducted through PubMed, Embase, Scopus, and Cochrane databases for relevant literature from inception up to May 2024. Six studies focusing on efficacy and safety aficamten was included. Pooled outcome estimates were reported as mean difference (MD) and 95 % CI using random effect model. Statistical heterogeneity was assessed using I²

SUBMITTER: Saddique MN 

PROVIDER: S-EPMC12002781 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature